Coinspeaker Moderna (MRNA) Stock Rises 10% after FDA Approves mRNA-1273 Vaccine for Phase 2 TrialPhase 2 trial of Moderna's coronavirus vaccine will shortly begin and enroll 600 participants. The company is also planning to begin phase 3 trial as early as this summer. MRNA stock is 10% up now.Moderna (MRNA) Stock Rises 10% after FDA Approves mRNA-1273 Vaccine for Phase 2 Trial